Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (41-50 of 222) with videos related to

Pageof 23
Sort By:
Cancers|October 3, 2020
A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer MedicineGift Nyamundanda, Katherine Eason, Justin Guinney, et al.
BMC Genomics|July 12, 2011
An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescenceEmilie Rovillain, Louise Mansfield, Christopher J Lord, et al.
Cell Systems|October 17, 2017
A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss EventsColm J Ryan, Susan Kennedy, Ilirjana Bajrami, et al.
Cancer Research|January 19, 2011
Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancersSarah A Martin, Madeleine Hewish, David Sims, et al.
DNA Repair|October 4, 2008
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityChristopher J Lord, Sarah McDonald, Sally Swift, et al.
Molecular & Cellular Oncology|May 28, 2019
Beyond DNA repair: the novel immunological potential of PARP inhibitorsRoman M Chabanon, Jean-Charles Soria, Christopher J Lord, et al.
Expert Opinion on Investigational Drugs|October 7, 2017
Directing the use of DDR kinase inhibitors in cancer treatmentInger Brandsma, Emmy D G Fleuren, Chris T Williamson, et al.
Nature Reviews. Clinical Oncology|February 24, 2010
Mismatch repair deficient colorectal cancer in the era of personalized treatmentMadeleine Hewish, Christopher J Lord, Sarah A Martin, et al.
Carcinogenesis|August 5, 2009
CRK7 modifies the MAPK pathway and influences the response to endocrine therapyElizabeth Iorns, Sanne R Martens-de Kemp, Christopher J Lord, et al.
EMBO Reports|September 11, 2004
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cellsKatrin Gudmundsdottir, Christopher J Lord, Emily Witt, et al.
Pageof 23

Showing results (41-50 of 222) with videos related to

Sort By:
Pageof 23
Cancers|October 3, 2020
A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer MedicineGift Nyamundanda, Katherine Eason, Justin Guinney, et al.
BMC Genomics|July 12, 2011
An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescenceEmilie Rovillain, Louise Mansfield, Christopher J Lord, et al.
Cell Systems|October 17, 2017
A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss EventsColm J Ryan, Susan Kennedy, Ilirjana Bajrami, et al.
Cancer Research|January 19, 2011
Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancersSarah A Martin, Madeleine Hewish, David Sims, et al.
DNA Repair|October 4, 2008
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityChristopher J Lord, Sarah McDonald, Sally Swift, et al.
Molecular & Cellular Oncology|May 28, 2019
Beyond DNA repair: the novel immunological potential of PARP inhibitorsRoman M Chabanon, Jean-Charles Soria, Christopher J Lord, et al.
Expert Opinion on Investigational Drugs|October 7, 2017
Directing the use of DDR kinase inhibitors in cancer treatmentInger Brandsma, Emmy D G Fleuren, Chris T Williamson, et al.
Nature Reviews. Clinical Oncology|February 24, 2010
Mismatch repair deficient colorectal cancer in the era of personalized treatmentMadeleine Hewish, Christopher J Lord, Sarah A Martin, et al.
Carcinogenesis|August 5, 2009
CRK7 modifies the MAPK pathway and influences the response to endocrine therapyElizabeth Iorns, Sanne R Martens-de Kemp, Christopher J Lord, et al.
EMBO Reports|September 11, 2004
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cellsKatrin Gudmundsdottir, Christopher J Lord, Emily Witt, et al.
Pageof 23